Summary:
- The BCG (Bacillus Calmette-Guérin) vaccine, traditionally used to prevent tuberculosis, has shown potential in treating type 1 diabetes by regulating the immune system.
- Clinical trials have demonstrated that the BCG vaccine can lead to a temporary reduction in blood sugar levels and an increase in C-peptide levels, which are indicators of insulin production, in individuals with type 1 diabetes.
- Researchers continue to investigate the mechanisms by which the BCG vaccine may help manage type 1 diabetes, with the goal of developing a safe and effective treatment option for this autoimmune condition.